Advanced Solid Tumor Clinical Trials in Minneapolis, Minnesota

5 studies are recruiting for advanced solid tumor in Minneapolis, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

   This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Minnesota Oncology and Hematology PA, Minneapolis, Minnesota

   Locations

   17 in total

   Run by

   Aulos Bioscience, Inc.

   See if you can join NCT05267626 on ClinicalTrials.gov

2. A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

   This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 to 89

   Site

   University of Minnesota-Clinical Research Unit, Minneapolis, Minnesota

   Locations

   57 in total

   Run by

   Eikon Therapeutics

   See if you can join NCT06253130 on ClinicalTrials.gov

3. GTB-5550 in Advanced Solid Tumors

   This is a first-in-human Phase 1a/1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the treatment of select solid tumor cancers. To be considered for the study, a patient must be 18 years or older, have histologically or cytologi…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT07541573 on ClinicalTrials.gov

4. First in Human Study of TORL-1-23 in Participants With Advanced Cancer

   This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Minnesota, Minneapolis, Minnesota

   Locations

   14 in total

   Run by

   TORL Biotherapeutics, LLC

   See if you can join NCT05103683 on ClinicalTrials.gov

5. FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

   This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Minnesota Medical School, Minneapolis, Minnesota

   Locations

   14 in total

   Run by

   Fate Therapeutics

   See if you can join NCT06241456 on ClinicalTrials.gov